|
Volumn 13, Issue 12, 2010, Pages 880-884
|
Advances in flavivirus vaccine development
|
Author keywords
Dengue fever; flavivirus; Japanese encephalitis; tick borne encephalitis; vaccine; West Nile virus; yellow fever
|
Indexed keywords
CHIMERIVAX DENGUE;
CHIMERIVAX JE;
CHIMERIVAX WEST NILE;
DENGUE VACCINE;
DENVAX;
DNA VACCINE;
FLAVIVIRUS VACCINE;
INACTIVATED VIRUS VACCINE;
JAPANESE ENCEPHALITIS VACCINE;
JE PIV;
LIVE VACCINE;
MGAWN 1;
MONOCLONAL ANTIBODY;
TICK BORNE ENCEPHALITIS VACCINE;
UNCLASSIFIED DRUG;
VIRUS VACCINE;
WEST NILE VACCINE;
XRX 001;
YELLOW FEVER VACCINE;
ANGIONEUROTIC EDEMA;
DENGUE;
DRUG EFFICACY;
DRUG SAFETY;
ENDEMIC DISEASE;
EPIDEMIC;
HIGH RISK POPULATION;
HUMAN;
IMMUNIZATION;
JAPANESE ENCEPHALITIS;
JAPANESE ENCEPHALITIS VIRUS;
NEUTROPENIA;
NONHUMAN;
RECOMBINANT DNA TECHNOLOGY;
RESPIRATORY DISTRESS;
REVIEW;
TICK BORNE ENCEPHALITIS;
UNITED STATES;
UNSPECIFIED SIDE EFFECT;
URTICARIA;
VACCINE PRODUCTION;
VIRUS STRAIN;
WEST NILE FEVER;
WEST NILE FLAVIVIRUS;
YELLOW FEVER;
ANIMALS;
FLAVIVIRUS;
FLAVIVIRUS INFECTIONS;
HUMANS;
VACCINES, SYNTHETIC;
VIRAL VACCINES;
|
EID: 79952762938
PISSN: 13697056
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
Times cited : (13)
|
References (6)
|